Building on the accuracy and reliability of the renowned Accu-Gold platform, the new MobileApp allows medical physicists, service engineers, and technicians to perform their QA workflows directly from a smartphone or tablet. Whether for radiography, fluoroscopy, mammography, or dental imaging, the app delivers instant access to real-time measurement data — without the need for a laptop or external PC.

“The Accu-Gold MobileApp brings a new level of freedom and efficiency to diagnostic QA,” says Daniel Boedeker, Director Product Lifecycle Management – Medical Imaging at IBA Dosimetry. “It combines the precision and trust of our Accu-Gold systems with the mobility today’s users expect in their daily work. You can perform measurements, review results, and store everything — all in the palm of your hand.”

The MobileApp connects seamlessly to Accu-Gold+ meters via WiFi, providing live readings of key parameters such as kV, dose, dose rate, exposure time, and HVL. Its intuitive interface, optimized for touch operation, features customizable displays and automatic data logging.

Beyond convenience, IBA Radcal focused on data integrity and workflow integration. Measurement data can be securely stored, exported, or shared for reporting and documentation — supporting both local and cloud-based QA processes.

“We developed the Accu-Gold Mobile to empower users to work wherever the measurement takes them — from clinical environments to field service,” Boedeker adds. “It’s a natural evolution of the Accu-Gold ecosystem, reflecting our ongoing commitment to innovation and user-centric design.”

With this release, IBA Radcal reaffirms its mission: delivering precision where it counts — and mobility where it matters.

Louvain-la-Neuve, Belgium, 03 November 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance.

Founded in 2018 by Dr. Paul Jahnke and Dr. Felix Schwarz, with support from Charité University Hospital in Berlin, PhantomX is a recognized leader in the development of realistic anthropomorphic phantoms. The company’s proprietary advanced quality assurance technologies are used globally for validating diagnostic and therapeutic imaging systems, as well as medical education and training. PhantomX is at the forefront of quality assurance for AI applications in medical imaging and provides tools for AI-enhanced clinical solutions.

“PhantomX’s expertise in AI validation perfectly complements IBA’s portfolio of Clinical Workflow Solutions in Radiation Therapy and Medical Imaging,” said Jean-Marc Bothy, President of IBA Dosimetry. “Together, we will accelerate innovation in our Medical Imaging Business Line with simulation and AI-driven technologies, delivering greater value to clinicians and patients worldwide.”

Dr. Paul Jahnke, one of the Founders of PhantomX, added: “This merger empowers us to bring our technology to new markets and contribute to the future of intelligent, safe, and effective medical solutions.”

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

For further information, please contact:

IBA Investor Relations
Thomas Pevenage
+32 10 475 890
investorrelations@iba-group.com

IBA Corporate Communication
Olivier Lechien
+32 10 475 890
communication@iba-group.com